PPARG and colorectal carcinoma: Furthermore, the research revealed that the administration of PPARγ antagonist and the process of PPARγ knockdown did not entirely impede the anticancer properties of HSYA, which suggested that other pathways were involved in HSYA-mediated CRC inhibition (Su and Lv, 2021).